Regeneron files $200 million shelf, repaying 5½% convertibles among possible aims

By Ted A. Knutson

Washington, Dec. 14 - Regeneron Pharmaceuticals Inc. filed a $200 million shelf, with one possible use of proceeds being the repayment or repurchase of its 5½% convertible senior subordinated notes due Oct. 17, 2008.

Included within the shelf are common stock, preferred stock, debt securities and warrants. The filing allows for convertibles.

In addition to debt repayment, money raised by shelf offerings may also be used for drug research, capital expenditures and other business purposes.

The Tarrytown, N.Y.-based drug company made the announcement in an S-3 registration with the Securities and Exchange Commission.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.